DeckTherapeutics Inc.

Name of License: 
DeckTherapeutics Inc.
By the: 
U.S. Army Medical Research & Development Command - Medical Technology Transfer Office (MTT)
On: 
Mar 20, 2020
Summary 

In accordance with applicable laws and regulations, announcement is made of the intent to grant an exclusive within a field of use, royalty-bearing, revocable license.

Tech Name: 
Intravenous Omega-3 Fatty Acid Compositions for Treatment of Traumatic Brain Injury
Action: 
Intent
Dates: 
March 20, 2020
Address: 
Commander, U.S. Army Medical Research and Development Command, ATTN: Director, Office of Research and Technology Applications, 1520 Freedman Drive, Suite 227, Fort Detrick, MD 21702-5012.
For further information contact 

Mr. Paul Michaels, Office of Research & Technology Applications, (301) 619-4145. For patent issues, Ms. Leigh Callander, Supervisory Patent Attorney, (301) 619-7808.

Supplementary information 

In accordance with 35 U.S.C. 209 (e) and 37 CFR 404.7 (a)(1)(i), announcement is made of the intent to grant an exclusive within a field of use, royalty-bearing, revocable license to United States Patent 9,675,572, filed April 22, 2011, entitled “Intravenous Omega-3 Fatty Acid Compositions and Methods of Use” to Deck Therapeutics Inc. having its principal place of business at 180 Varick Street, 6th Floor, New York, NY 10014.
Anyone wishing to object to grant of this license can file written objections along with supporting evidence, if any, within 15 days from the date of this publication. Written objections are to be filed with the Director, Office of Research and Technology Applications (see ADDRESSES).

Correction: 
Upload PDF: 
PDF icon flc_business_notice_decktherapeutics_inc_20march2020.pdf